Analgesic efficacy of imrecoxib for postoperative pain following oral surgery: a prospective randomized, active-controlled, non-inferiority trial

BACKGROUND: Imrecoxib, a novel cyclooxygenase (COX-2) selective non-steroidal anti-inflammatory drug (NSAID), has been approved in China for more than 9 years. This study aimed to assess the efficacy and safety of imrecoxib compared with celecoxib for patients with moderate or severe acute pain foll...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yu, Qi, Lili, Liu, Jie, Wu, Heming, Li, Yi, Zou, Linhu, Guo, Zhiwei, Wang, Jinqiang, Li, Huaiqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039693/
https://www.ncbi.nlm.nih.gov/pubmed/33850866
http://dx.doi.org/10.21037/atm-21-264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039693/
https://www.ncbi.nlm.nih.gov/pubmed/33850866
http://dx.doi.org/10.21037/atm-21-264

Ejemplares similares